Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have reported that the European Commission has granted marketing authorization to Nexavar tablets for the treatment of patients with hepatocellular carcinoma, the most common form of liver cancer.
Subscribe to our email newsletter
The European Commission’s decision to approve Nexavar is based on positive data from the international Phase III placebo-controlled sorafenib hepatocellular carcinoma (HCC) assessment randomized protocol (SHARP) trial, which demonstrated that Nexavar extended overall survival by 44% in patients with HCC versus placebo.
Arthur Higgins, chairman of the executive committee of Bayer HealthCare, said: “The approval of Nexavar, a novel multi-kinase inhibitor, represents an unprecedented advance for patients with HCC who, until now, had no approved systemic treatment options. This milestone will likely establish Nexavar as the standard systemic therapy for the treatment of HCC and shows the dedication of health authorities to make Nexavar available as quickly as possible.”